(BIM) Biomerieux - Overview
Exchange: PA •
Country: France •
Currency: EUR •
Type: Common Stock •
ISIN: FR0013280286
Stock:
Total Rating 44
Risk 86
Buy Signal -1.01
| Risk 5d forecast | |
|---|---|
| Volatility | 22.4% |
| Relative Tail Risk | -6.41% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.95 |
| Alpha | -24.29 |
| Character TTM | |
|---|---|
| Beta | 0.325 |
| Beta Downside | 0.063 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.14% |
| CAGR/Max DD | 0.01 |
Description: BIM Biomerieux
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Piotroski VR‑10 (Strict, 0-10) 9.5
| Net Income: 660.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 8.46 > 1.0 |
| NWC/Revenue: 18.68% < 20% (prev 19.94%; Δ -1.26% < -1%) |
| CFO/TA 0.24 > 3% & CFO 1.28b > Net Income 660.4m |
| Net Debt (125.9m) to EBITDA (1.53b): 0.08 < 3 |
| Current Ratio: 2.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (118.9m) vs 12m ago -0.04% < -2% |
| Gross Margin: 54.80% > 18% (prev 0.52%; Δ 5428 % > 0.5%) |
| Asset Turnover: 128.2% > 50% (prev 106.6%; Δ 21.57% > 0%) |
| Interest Coverage Ratio: 40.01 > 6 (EBITDA TTM 1.53b / Interest Expense TTM 25.9m) |
Altman Z'' 2.93
| A: 0.24 (Total Current Assets 2.28b - Total Current Liabilities 1.00b) / Total Assets 5.37b |
| B: 0.03 (Retained Earnings 161.0m / Total Assets 5.37b) |
| C: 0.19 (EBIT TTM 1.03b / Avg Total Assets 5.31b) |
| D: -0.03 (Book Value of Equity -48.6m / Total Liabilities 1.43b) |
| Altman-Z'' Score: 2.93 = A |
Beneish M -3.36
| DSRI: 0.65 (Receivables 688.4m/865.5m, Revenue 6.81b/5.61b) |
| GMI: 0.95 (GM 54.80% / 51.83%) |
| AQI: 0.95 (AQ_t 0.28 / AQ_t-1 0.29) |
| SGI: 1.21 (Revenue 6.81b / 5.61b) |
| TATA: -0.12 (NI 660.4m - CFO 1.28b) / TA 5.37b) |
| Beneish M-Score: -3.36 (Cap -4..+1) = AA |
What is the price of BIM shares?
As of February 24, 2026, the stock is trading at EUR 94.70 with a total of 167,762 shares traded.
Over the past week, the price has changed by +2.38%, over one month by -8.68%, over three months by -12.88% and over the past year by -16.53%.
Over the past week, the price has changed by +2.38%, over one month by -8.68%, over three months by -12.88% and over the past year by -16.53%.
Is BIM a buy, sell or hold?
Biomerieux has no consensus analysts rating.
What are the forecasts/targets for the BIM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 119.1 | 25.8% |
| Analysts Target Price | - | - |
BIM Fundamental Data Overview February 23, 2026
Market Cap USD = 13.25b (11.25b EUR * 1.1784 EUR.USD)
P/E Trailing = 30.0473
P/E Forward = 24.3309
P/S = 2.7284
P/B = 2.7672
P/EG = 1.9454
Revenue TTM = 6.81b EUR
EBIT TTM = 1.03b EUR
EBITDA TTM = 1.53b EUR
Long Term Debt = 212.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 172.1m EUR (from shortTermDebt, last quarter)
Debt = 506.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 125.9m EUR (from netDebt column, last quarter)
Enterprise Value = 11.59b EUR (11.25b + Debt 506.4m - CCE 158.4m)
Interest Coverage Ratio = 40.01 (Ebit TTM 1.03b / Interest Expense TTM 25.9m)
EV/FCF = 19.46x (Enterprise Value 11.59b / FCF TTM 595.8m)
FCF Yield = 5.14% (FCF TTM 595.8m / Enterprise Value 11.59b)
FCF Margin = 8.75% (FCF TTM 595.8m / Revenue TTM 6.81b)
Net Margin = 9.70% (Net Income TTM 660.4m / Revenue TTM 6.81b)
Gross Margin = 54.80% ((Revenue TTM 6.81b - Cost of Revenue TTM 3.08b) / Revenue TTM)
Gross Margin QoQ = 57.09% (prev 51.87%)
Tobins Q-Ratio = 2.16 (Enterprise Value 11.59b / Total Assets 5.37b)
Interest Expense / Debt = 1.48% (Interest Expense 7.50m / Debt 506.4m)
Taxrate = 24.67% (52.6m / 213.2m)
NOPAT = 779.2m (EBIT 1.03b * (1 - 24.67%))
Current Ratio = 2.27 (Total Current Assets 2.28b / Total Current Liabilities 1.00b)
Debt / Equity = 0.13 (Debt 506.4m / totalStockholderEquity, last quarter 3.93b)
Debt / EBITDA = 0.08 (Net Debt 125.9m / EBITDA 1.53b)
Debt / FCF = 0.21 (Net Debt 125.9m / FCF TTM 595.8m)
Total Stockholder Equity = 3.94b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.43% (Net Income 660.4m / Total Assets 5.37b)
RoE = 16.76% (Net Income TTM 660.4m / Total Stockholder Equity 3.94b)
RoCE = 24.91% (EBIT 1.03b / Capital Employed (Equity 3.94b + L.T.Debt 212.8m))
RoIC = 18.32% (NOPAT 779.2m / Invested Capital 4.25b)
WACC = 6.85% (E(11.25b)/V(11.75b) * Re(7.11%) + D(506.4m)/V(11.75b) * Rd(1.48%) * (1-Tc(0.25)))
Discount Rate = 7.11% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.02%
[DCF Debug] Terminal Value 85.09% ; FCFF base≈413.0m ; Y1≈509.5m ; Y5≈867.7m
Fair Price DCF = 160.4 (EV 19.06b - Net Debt 125.9m = Equity 18.94b / Shares 118.1m; r=6.85% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -9.53 | EPS CAGR: -47.24% | SUE: 0.0 | # QB: 0
Revenue Correlation: 9.02 | Revenue CAGR: 7.57% | SUE: 1.17 | # QB: 1
EPS next Year (2026-12-31): EPS=4.86 | Chg30d=-0.068 | Revisions Net=-7 | Growth EPS=+5.5% | Growth Revenue=+5.0%
P/E Trailing = 30.0473
P/E Forward = 24.3309
P/S = 2.7284
P/B = 2.7672
P/EG = 1.9454
Revenue TTM = 6.81b EUR
EBIT TTM = 1.03b EUR
EBITDA TTM = 1.53b EUR
Long Term Debt = 212.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 172.1m EUR (from shortTermDebt, last quarter)
Debt = 506.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 125.9m EUR (from netDebt column, last quarter)
Enterprise Value = 11.59b EUR (11.25b + Debt 506.4m - CCE 158.4m)
Interest Coverage Ratio = 40.01 (Ebit TTM 1.03b / Interest Expense TTM 25.9m)
EV/FCF = 19.46x (Enterprise Value 11.59b / FCF TTM 595.8m)
FCF Yield = 5.14% (FCF TTM 595.8m / Enterprise Value 11.59b)
FCF Margin = 8.75% (FCF TTM 595.8m / Revenue TTM 6.81b)
Net Margin = 9.70% (Net Income TTM 660.4m / Revenue TTM 6.81b)
Gross Margin = 54.80% ((Revenue TTM 6.81b - Cost of Revenue TTM 3.08b) / Revenue TTM)
Gross Margin QoQ = 57.09% (prev 51.87%)
Tobins Q-Ratio = 2.16 (Enterprise Value 11.59b / Total Assets 5.37b)
Interest Expense / Debt = 1.48% (Interest Expense 7.50m / Debt 506.4m)
Taxrate = 24.67% (52.6m / 213.2m)
NOPAT = 779.2m (EBIT 1.03b * (1 - 24.67%))
Current Ratio = 2.27 (Total Current Assets 2.28b / Total Current Liabilities 1.00b)
Debt / Equity = 0.13 (Debt 506.4m / totalStockholderEquity, last quarter 3.93b)
Debt / EBITDA = 0.08 (Net Debt 125.9m / EBITDA 1.53b)
Debt / FCF = 0.21 (Net Debt 125.9m / FCF TTM 595.8m)
Total Stockholder Equity = 3.94b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.43% (Net Income 660.4m / Total Assets 5.37b)
RoE = 16.76% (Net Income TTM 660.4m / Total Stockholder Equity 3.94b)
RoCE = 24.91% (EBIT 1.03b / Capital Employed (Equity 3.94b + L.T.Debt 212.8m))
RoIC = 18.32% (NOPAT 779.2m / Invested Capital 4.25b)
WACC = 6.85% (E(11.25b)/V(11.75b) * Re(7.11%) + D(506.4m)/V(11.75b) * Rd(1.48%) * (1-Tc(0.25)))
Discount Rate = 7.11% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.02%
[DCF Debug] Terminal Value 85.09% ; FCFF base≈413.0m ; Y1≈509.5m ; Y5≈867.7m
Fair Price DCF = 160.4 (EV 19.06b - Net Debt 125.9m = Equity 18.94b / Shares 118.1m; r=6.85% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -9.53 | EPS CAGR: -47.24% | SUE: 0.0 | # QB: 0
Revenue Correlation: 9.02 | Revenue CAGR: 7.57% | SUE: 1.17 | # QB: 1
EPS next Year (2026-12-31): EPS=4.86 | Chg30d=-0.068 | Revisions Net=-7 | Growth EPS=+5.5% | Growth Revenue=+5.0%